Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-TECHNE CorpTECH · Entity 3479 | Director | September 28, 2026 | September 30, 2026 |
| LIGAND PHARMACEUTICALS INCLGND · Entity 3825 | Director | December 28, 2022 | December 30, 2022 |
| OmniAb, Inc.OABI · Entity 5294 | Director | June 17, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-TECHNE Corp
Report date September 28, 2026 · Filed September 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 77,254 |
Ending reported balance
After 2026-09-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-28 · Exercise / conversion · Acquired 15,940 · Balance 82,816 Row 2 · 2026-09-28 · Tax withholding · Disposed 5,562 · Balance 77,254 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.30 · Expires 2026-10-26 | Direct | 0 |
Reported balance
After 2026-09-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-28 · Exercise / conversion · Disposed 15,940 · Balance 0 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.26 · Expires 2027-10-26 | Direct | 12,500 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 12,500 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.96 · Expires 2028-10-25 | Direct | 7,592 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 7,592 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.41 · Expires 2029-10-24 | Direct | 8,044 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 8,044 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.92 · Expires 2030-10-29 | Direct | 6,028 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 6,028 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $128.81 · Expires 2031-10-28 | Direct | 2,532 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 2,532 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $73.94 · Expires 2032-10-27 | Direct | 3,460 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 3,460 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.51 · Expires 2033-10-26 | Direct | 3,937 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 3,937 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.37 · Expires 2034-10-24 | Direct | 3,511 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 3,511 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.96 · Expires 2035-10-30 | Direct | 3,777 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 3,777 F1: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
LIGAND PHARMACEUTICALS INC
Report date December 28, 2022 · Filed December 30, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 417,695 |
Reported balance
After 2022-12-28 transaction · row 1
1 source rowRow 1 · 2022-12-28 · Tax withholding · Disposed 5,289 · Balance 417,695 |
OmniAb, Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,962,320 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Exercise / conversion · Acquired 20,000 · Balance 2,962,320 F1: Represents the vesting of an RSU granted on June 17, 2025, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Exercise / conversion · Disposed 20,000 · Balance 0 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1: Represents the vesting of an RSU granted on June 17, 2025, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 20,000 |
Reported balance
After 2026-06-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-17 · Grant · Acquired 20,000 · Balance 20,000 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3: The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.03 · Expires 2036-06-17 | Direct | 40,000 |
Reported balance
After 2026-06-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-17 · Grant · Acquired 40,000 · Balance 40,000 F4: Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the vesting of an RSU granted on June 17, 2025, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date.
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F3: The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date.
F4: Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2022 Filed Jun 14, 2022 21:55 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 20,423 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-22-000091 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,016 Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 21:07 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 600 | $0.00 Strike: $66.90 | $0.00 |
DisclosureSEC source: 0001415889-22-006392 · form4-06092022_020600.xml · derivative · entry 6 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,400 Underlying: Common Stock · 4,000 shares Expires 2022-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 21:07 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 600 | $366.09 | $219,654.00 |
DisclosureSEC source: 0001415889-22-006392 · form4-06092022_020600.xml · nonDerivative · entry 4 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,606 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 366.0000 to 366.1900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 21:07 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 600 | $66.90 | $40,140.00 |
DisclosureSEC source: 0001415889-22-006392 · form4-06092022_020600.xml · nonDerivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:07 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $66.90 | $0.00 |
DisclosureSEC source: 0001415889-22-006392 · form4-06092022_020600.xml · derivative · entry 5 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 5,000 shares Expires 2022-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:07 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,000 | $364.31 | $364,310.00 |
DisclosureSEC source: 0001415889-22-006392 · form4-06092022_020600.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,606 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 364.0000 to 364.6400, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:07 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 1,000 | $66.90 | $66,900.00 |
DisclosureSEC source: 0001415889-22-006392 · form4-06092022_020600.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,606 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2022 Filed May 10, 2022 21:33 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Sale0.75% Convertible Senior Notes due 2023 · Derivative | Not disclosed | $429,159.38 Strike: $248.48 | $450,000.00 |
DisclosureSEC source: 0000886163-22-000060 · edgardoc.xml · derivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · Not disclosed shares Expires 2023-05-15 F1 · derivative.exercise_date: The notes are convertible at any time prior to the close of business on November 14, 2022 (1) during any fiscal quarter (and only during such fiscal quarter) commencing after September 30, 2018, if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of the Issuer?s common stock on such trading day is greater than 130% of the conversion price on such trading day; (2) during the five business day period immediately following any 10 consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than 98% of the product of the last reported sale price of our common stock on such trading day and the conversion rate on each such trading day; or (3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes. Read SEC document |
| May 09, 2022 Filed May 10, 2022 21:33 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $21.92 | $0.00 |
DisclosureSEC source: 0000886163-22-000060 · edgardoc.xml · derivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,616 Underlying: Common Stock · 8,000 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13. Read SEC document |
| May 09, 2022 Filed May 10, 2022 21:33 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 8,000 | $21.92 | $175,360.00 |
DisclosureSEC source: 0000886163-22-000060 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,593 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2022 Filed May 10, 2022 00:09 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 76,478 | $0.00 Strike: $90.68 | $0.00 |
DisclosureSEC source: 0000886163-22-000054 · edgardoc.xml · derivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,478 Underlying: Common Stock · 76,478 shares Expires 2032-05-05 F1 · derivative.exercise_date: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exerciseable over a 3-year, 9-month period measured from the date of grant, 12-1/2% after three months, then 1/48th of the Option Shares per month thereafter. The date of grant is 05/05/2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 01:23 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,916 | $123.68 | $236,970.88 |
DisclosureSEC source: 0000886163-22-000022 · edgardoc.xml · nonDerivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,593 F3 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/03/2021. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 01:23 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 2,061 | $123.68 | $254,904.48 |
DisclosureSEC source: 0000886163-22-000022 · edgardoc.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,509 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/13/2020. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 01:23 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,946 | $123.68 | $240,681.28 |
DisclosureSEC source: 0000886163-22-000022 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,570 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2019. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 01:42 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 6,183 | $113.68 | $702,883.44 |
DisclosureSEC source: 0000886163-22-000013 · edgardoc.xml · nonDerivative · entry 4 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,018 F3 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 01:42 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 3,060 | $113.68 | $347,860.80 |
DisclosureSEC source: 0000886163-22-000013 · edgardoc.xml · nonDerivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,201 F3 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 01:42 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 13,560 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-22-000013 · edgardoc.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 358,261 F2 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 03/09/2020 and were eligible to vest based on the Issuer achievement of certain performance objectives during the two-year performance period ending December 31, 2021. On January 26, 2022, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 01:42 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 9,606 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-22-000013 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,701 F1 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 05/29/2019 and were eligible to vest based on the Issuer achievement of certain performance objectives during the three-year performance period ending December 31, 2021. On January 26, 2022, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| November 15, 2021 Filed Feb 8, 2022 00:29 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GiftCommon Stock | 2,502 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-22-000016 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,593 F1 · price: Charitable gift to a third party. Read SEC document |
| November 12, 2021 Filed Nov 13, 2021 00:31 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 3,000 | $160.50 | $481,500.00 |
DisclosureSEC source: 0000886163-21-000134 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,095 Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 20:41 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (right to buy) · Derivative | 633 | $0.00 Strike: $515.24 | $0.00 |
DisclosureSEC source: 0000914190-21-000399 · edgar.xml · derivative · entry 11 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 633 Underlying: Common Stock · 633 shares Expires 2031-10-28 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/28/21) or the date of Bio-Techne's 2022 annual meeting of shareholders. Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 20:41 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 194 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000399 · edgar.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,606 Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:14 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | OtherCommon Stock | 247 | $85.91 | $21,219.65 |
DisclosureSEC source: 0000886163-21-000098 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,095 F1 · kind: Shares acquired under Ligand's employee stock purchase plan. Voluntary reporting exemption under Rule 16b-3(c). Read SEC document |
| February 15, 2021 Filed Feb 18, 2021 23:27 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 2,061 | $172.46 | $355,440.06 |
DisclosureSEC source: 0000886163-21-000041 · edgardoc.xml · nonDerivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,848 F3 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/13/2020. Read SEC document |
| February 15, 2021 Filed Feb 18, 2021 23:27 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,947 | $172.46 | $335,779.62 |
DisclosureSEC source: 0000886163-21-000041 · edgardoc.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,909 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2019. Read SEC document |
| February 15, 2021 Filed Feb 18, 2021 23:27 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,204 | $172.46 | $207,641.84 |
DisclosureSEC source: 0000886163-21-000041 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,856 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 03/02/2018. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 23:08 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 54,666 | $0.00 Strike: $14.47 | $0.00 |
DisclosureSEC source: 0000886163-21-000033 · edgardoc.xml · derivative · entry 6 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,334 Underlying: Common Stock · 54,666 shares Expires 2022-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 10, 2020, in accordance with Rule 10b5-1. F5 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/09/12. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 23:08 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0000886163-21-000033 · edgardoc.xml · derivative · entry 5 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2021-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/17/11. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 23:08 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 2,970 | $203.03 | $602,999.10 |
DisclosureSEC source: 0000886163-21-000033 · edgardoc.xml · nonDerivative · entry 4 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,060 F3 · shares: Represents previously-owned shares delivered to the Issuer in payment of the exercise price of the stock options. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 23:08 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 60,000 | $10.05 | $603,000.00 |
DisclosureSEC source: 0000886163-21-000033 · edgardoc.xml · nonDerivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 23:08 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 54,666 | $203.40 | $11,119,239.33 |
DisclosureSEC source: 0000886163-21-000033 · edgardoc.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,030 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.00 to $201.29, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 23:08 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 54,666 | $14.47 | $791,017.02 |
DisclosureSEC source: 0000886163-21-000033 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 10, 2020, in accordance with Rule 10b5-1. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 22:02 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 25,113 | $0.00 Strike: $177.50 | $0.00 |
DisclosureSEC source: 0000886163-21-000028 · edgardoc.xml · derivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,113 Underlying: Common Stock · 25,113 shares Expires 2031-02-03 F1 · derivative.exercise_date: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exerciseable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/03/2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 22:02 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 12,608 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-21-000028 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,030 Read SEC document |
| January 27, 2021 Filed Jan 28, 2021 00:04 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $21.92 | $0.00 |
DisclosureSEC source: 0000886163-21-000016 · edgardoc.xml · derivative · entry 12 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,616 Underlying: Common Stock · 30,000 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13. Read SEC document |
| January 27, 2021 Filed Jan 28, 2021 00:04 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $14.47 | $0.00 |
DisclosureSEC source: 0000886163-21-000016 · edgardoc.xml · derivative · entry 11 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,000 Underlying: Common Stock · 40,000 shares Expires 2022-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 10, 2020, in accordance with Rule 10b5-1. F6 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/09/12. Read SEC document |
| January 27, 2021 Filed Jan 28, 2021 00:04 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 30,000 | $21.92 | $657,600.00 |
DisclosureSEC source: 0000886163-21-000016 · edgardoc.xml · nonDerivative · entry 9 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2021 Filed Jan 28, 2021 00:04 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 40,000 | $182.00 | $7,280,000.00 |
DisclosureSEC source: 0000886163-21-000016 · edgardoc.xml · nonDerivative · entry 8 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,422 F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 10, 2020, in accordance with Rule 10b5-1. Read SEC document |
| January 27, 2021 Filed Jan 28, 2021 00:04 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 40,000 | $14.47 | $578,800.00 |
DisclosureSEC source: 0000886163-21-000016 · edgardoc.xml · nonDerivative · entry 7 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 10, 2020, in accordance with Rule 10b5-1. Read SEC document |
| January 25, 2021 Filed Jan 28, 2021 00:04 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $14.47 | $0.00 |
DisclosureSEC source: 0000886163-21-000016 · edgardoc.xml · derivative · entry 10 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,000 Underlying: Common Stock · 50,000 shares Expires 2022-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 10, 2020, in accordance with Rule 10b5-1. F6 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/09/12. Read SEC document |
| January 25, 2021 Filed Jan 28, 2021 00:04 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 4,596 | $156.01 | $717,021.96 |
DisclosureSEC source: 0000886163-21-000016 · edgardoc.xml · nonDerivative · entry 6 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,422 F4 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
| January 25, 2021 Filed Jan 28, 2021 00:04 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 9,607 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-21-000016 · edgardoc.xml · nonDerivative · entry 5 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,018 F5 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 05/29/2019 and were eligible to vest based on the Issuer achievement of certain performance objectives during the two-year performance period ending December 31, 2020. On January 25, 2021, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| January 25, 2021 Filed Jan 28, 2021 00:04 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 2,845 | $156.01 | $443,848.45 |
DisclosureSEC source: 0000886163-21-000016 · edgardoc.xml · nonDerivative · entry 4 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,411 F4 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
| January 25, 2021 Filed Jan 28, 2021 00:04 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 5,946 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-21-000016 · edgardoc.xml · nonDerivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,256 F3 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 05/30/2018 and were eligible to vest based on the Issuer achievement of certain performance objectives during the three-year performance period ending December 31, 2020. On January 25, 2021, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| January 25, 2021 Filed Jan 28, 2021 00:04 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 50,000 | $159.00 | $7,950,000.00 |
DisclosureSEC source: 0000886163-21-000016 · edgardoc.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,310 F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 10, 2020, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.00 to $165.00, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 25, 2021 Filed Jan 28, 2021 00:04 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 50,000 | $14.47 | $723,500.00 |
DisclosureSEC source: 0000886163-21-000016 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,310 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 10, 2020, in accordance with Rule 10b5-1. Read SEC document |
| December 31, 2020 Filed Jan 6, 2021 01:30 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | OtherCommon Stock | 223 | $84.53 | $18,850.75 |
DisclosureSEC source: 0000886163-21-000003 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,310 F1 · kind: Shares acquired under Ligand's employee stock purchase plan. Voluntary reporting exemption under Rule 16b-3(c). Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 23:12 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 14,657 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0000886163-20-000133 · edgardoc.xml · derivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 14,657 shares Expires 2021-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/17/11. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 23:12 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,683 | $87.52 | $147,296.16 |
DisclosureSEC source: 0000886163-20-000133 · edgardoc.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,087 F1 · shares: Represents previously-owned shares delivered to the Issuer in payment of the exercise price of the stock options. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 23:12 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 14,657 | $10.05 | $147,302.85 |
DisclosureSEC source: 0000886163-20-000133 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.